Home > > > > > Report Detail

Attention-deficit/hyperactivity disorder (ADHD) - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Attention-deficit/hyperactivity disorder (ADHD) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Attention-deficit/hyperactivity disorder (ADHD) epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Attention-deficit/hyperactivity disorder (ADHD) Understanding and Treatment Algorithm

The market report provides the overview of the Attention-deficit/hyperactivity disorder (ADHD) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Attention-deficit/hyperactivity disorder (ADHD) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Attention-deficit/hyperactivity disorder (ADHD) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Attention-deficit/hyperactivity disorder (ADHD) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Attention-deficit/hyperactivity disorder (ADHD) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Attention-deficit/hyperactivity disorder (ADHD) market.

Attention-deficit/hyperactivity disorder (ADHD) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Attention-deficit/hyperactivity disorder (ADHD) Report Insights

- Patient Population in Attention-deficit/hyperactivity disorder (ADHD)

- Therapeutic Approaches in Attention-deficit/hyperactivity disorder (ADHD)

- Attention-deficit/hyperactivity disorder (ADHD) Pipeline Analysis

- Attention-deficit/hyperactivity disorder (ADHD) Market Size and Trends

- Attention-deficit/hyperactivity disorder (ADHD) Market Opportunities

- Impact of upcoming Therapies in Attention-deficit/hyperactivity disorder (ADHD)

Attention-deficit/hyperactivity disorder (ADHD) Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Attention-deficit/hyperactivity disorder (ADHD) Report Assessment

- Current Treatment Practices in Attention-deficit/hyperactivity disorder (ADHD)

- Unmet Needs in Attention-deficit/hyperactivity disorder (ADHD)

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Attention-deficit/hyperactivity disorder (ADHD) market

- Organize sales and marketing efforts by identifying the best opportunities for Attention-deficit/hyperactivity disorder (ADHD) market

- To understand the future market competition in the Attention-deficit/hyperactivity disorder (ADHD) market.

Attention-deficit/hyperactivity disorder (ADHD) - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Attention-deficit/hyperactivity disorder (ADHD) Market Overview at a Glance
2.1. Market Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2016
2.2. Market Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2028
3. Disease Background and Overview: Attention-deficit/hyperactivity disorder (ADHD)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM
4.3. Total Prevalent Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM - By Countries
5. Epidemiology of Attention-deficit/hyperactivity disorder (ADHD) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.1.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.1.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.1.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.1.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.4.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.4.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.4.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.4.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.5.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.5.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.5.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.5.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.6.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.6.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.6.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.6.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.7.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.7.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.7.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.7.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.8.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.8.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.8.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.8.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.9.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.9.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.9.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.9.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Attention-deficit/hyperactivity disorder (ADHD)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Attention-deficit/hyperactivity disorder (ADHD)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Attention-deficit/hyperactivity disorder (ADHD) : 7MM Market Analysis
12.1. 7MM Market Size of Attention-deficit/hyperactivity disorder (ADHD)
12.2. 7MM Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD)
12.3. 7MM Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products
13. Attention-deficit/hyperactivity disorder (ADHD) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in United States
13.1.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in United States
13.1.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Germany
13.2.1.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Germany
13.2.1.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in France
13.2.2.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in France
13.2.2.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Italy
13.2.3.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Italy
13.2.3.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Spain
13.2.4.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Spain
13.2.4.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in United Kingdom
13.2.5.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Japan
13.3.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Japan
13.3.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 7: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 12: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 15: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 16: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 17: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 22: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 27: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 31: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 32: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 37: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 42:7MM- Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 45: United States-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 48: Germany-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 51: France-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 54: Italy-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 57: Spain-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 60:UK-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 63: Japan-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 7: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 12: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 16: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 17: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 22: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 27: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 32: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 37: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 42:7MM- Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 45: United States-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 48: Germany-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 51: France-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 54: Italy-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 57: Spain-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 60:UK-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 63: Japan-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)

  • Global Divalproex Sodium Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 81
    Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in The brain tissue to stop seizures. Divalproex Sodium is also used to treat The manic phase of bipolar disorder (manic-depressive illness), and helps prevent migraine headaches. This medicine is available only with your doctor's prescription. The global Divalproex Sodium market was valued at US$ 2188.5 million in 2023 and is anticipated to reach US$ 33......
  • Global Divalproex Sodium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 90
    According to our LPI (LP Information) latest study, the global Divalproex Sodium market size was valued at US$ 2140.9 million in 2023. With growing demand in downstream market, the Divalproex Sodium is forecast to a readjusted size of US$ 3312 million by 2030 with a CAGR of 6.4% during review period. The research report highlights the growth potential of the global Divalproex Sodium market. Divalproex Sodium are expected to show stable growth in the future market. However, product differ......
  • Global Quetiapine Fumarate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Quetiapine Fumarate market size was valued at US$ 156.2 million in 2023. With growing demand in downstream market, the Quetiapine Fumarate is forecast to a readjusted size of US$ 132.9 million by 2030 with a CAGR of -2.3% during review period. The research report highlights the growth potential of the global Quetiapine Fumarate market. Quetiapine Fumarate are expected to show stable growth in the future market. However, produ......
  • Global Clozapine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 114
    According to our LPI (LP Information) latest study, the global Clozapine market size was valued at US$ 341.4 million in 2023. With growing demand in downstream market, the Clozapine is forecast to a readjusted size of US$ 463.4 million by 2030 with a CAGR of 4.5% during review period. The research report highlights the growth potential of the global Clozapine market. Clozapine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and s......
  • Global Trazodone Hydrochloride (API) Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 92
    According to our LPI (LP Information) latest study, the global Trazodone Hydrochloride (API) market size was valued at US$ million in 2023. With growing demand in downstream market, the Trazodone Hydrochloride (API) is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Trazodone Hydrochloride (API) market. Trazodone Hydrochloride (API) are expected to show stable growth in the future......
  • Global Trazodone Hydrochloride (API) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 93
    According to our (Global Info Research) latest study, the global Trazodone Hydrochloride (API) market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period. Trazodone, a phenylpiperazine-triazolopyridine antidepressant, was originally discovered and developed in Italy in the 1970s by Angelini research laboratories. Trazodone is used to treat depression and to treat the combination of symptoms of anxiety an......
  • Global Divalproex Sodium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 91
    According to our (Global Info Research) latest study, the global Divalproex Sodium market size was valued at USD 2251.9 million in 2023 and is forecast to a readjusted size of USD 3371.1 million by 2030 with a CAGR of 5.9% during review period. Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in the brain tissue to stop seizures. Divalproex Sodium is also used to treat the manic phase of bipolar disorder (manic-d......
  • Global Risperidone Market Research Report 2023
    Published: 28-Dec-2023        Price: US 2900 Onwards        Pages: 93
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Risperidone market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Janssen (Johnson & Johnson) - Ajanta Pharma - Amneal Pharmaceuticals - Aurobindo Pharma - Hikma - Sandoz - Lannett - Tris Pharma - Ap......
  • Global Schizophrenia Therapeutics Market Status and Outlook 2023-2028
    Published: 27-Dec-2023        Price: US 3160 Onwards        Pages: 101
    Schizophrenia is usually treated with an individually tailored combination of talking therapy and medicine. Most people with schizophrenia are treated by community mental health teams (CMHTs). The goal of the CMHT is to provide day-to-day support and treatment while ensuring you have as much independence as possible. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market va......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs